NuriBio Co., Ltd. is a genetic analysis company using proprietary technology, PROMER(Probe+Primer). We are dedicated in research and development of customized genetic analsysis kits for research and medical fields.
Our Promer technology is specialized in analyzing genes such as miRNA, Point Mutation, and SNP. We are able to supply customized products needed in research settings. Furthermore, through in-house R&D we are able to supply cancer screening kits and companion diagnostic kits that enable early cancer diagnosis through liquid biopsy. In particular, our miRNA analysis service is expanding from miRNA screening to analysis and spatial biology, and we are developing various disease screening and analysis kits using proprietary technology. We aim to grow into a company that reflects the needs of research and medical fields and provide products and solutions that increases medical accessibility to everyone.
HISTORY
2014
ㆍNuriBio Co., Ltd. Founded
2015
ㆍVenture Business Certification (Kibo Technology Fund)
2016
ㆍDepartment dedicated to R&D Certificate (KOITA)
2017
ㆍCtrl-X Trademark Registration (No. 40-1436085, No. 2001455212)
ㆍSeoul National University Joint-Research Agreement
ㆍSeoul National University Joint-Research Agreement
2018
ㆍIndustrial R&D Center Certification (KOITA)
ㆍJohns Hopkins University Joint-Research Agreement
ㆍBayer Grants4Apps Accelerator Program Selection
ㆍTIPS Selection (Tech Incubator Program for startup Korea)
ㆍAsia Herald 2018 Republic of Korea Investment: Startup Category Grand Prize
ㆍJohns Hopkins University Joint-Research Agreement
ㆍBayer Grants4Apps Accelerator Program Selection
ㆍTIPS Selection (Tech Incubator Program for startup Korea)
ㆍAsia Herald 2018 Republic of Korea Investment: Startup Category Grand Prize
2019
ㆍISO 13485:2016 (Institue of Global Certification)
ㆍStartup Growth Technology Development Project
- Innovation Growth Package (Ministry of SMEs and Startups)
ㆍThe 13th Republic of Korea Excellent Patent - Grand Prize
ㆍStartup Growth Technology Development Project
- Innovation Growth Package (Ministry of SMEs and Startups)
ㆍThe 13th Republic of Korea Excellent Patent - Grand Prize
2020
ㆍKOTRA Global Jump 300 Selection
2021
ㆍGenetic Testing Agency Declaration (No. 380)
ㆍSelected as participant of 'Special regulation-free zone - Innovative Business Promotion'
ㆍSelected as participant of 'Special regulation-free zone - Innovative Business Promotion'
2023
ㆍGMP (In Vitro Diagnostic Medical Device Manufacturing)
ㆍEN ISO 13485:2016 (LL-C Certification)
ㆍSelected as Industrial Technology Innovation Project 'Development of materials and parts technology' (Ministry of Trade, Industry and Energy)
ㆍEN ISO 13485:2016 (LL-C Certification)
ㆍSelected as Industrial Technology Innovation Project 'Development of materials and parts technology' (Ministry of Trade, Industry and Energy)
2024
ㆍCertificate of Manufacturer (MFDS, Registered No. 8559)
ㆍCtrl-X® ApoE Genotyping qPCR Kit (MFDS, Product-License No. 24-570)
ㆍCtrl-X® BRAF V600E Mutation Detection Kit (Product-License No. 24-758)
ㆍCtrl-X® KRAS G12C Mutation Detection Kit (Product-License No. 24-710)
ㆍCtrl-X® EGFR L858R Mutation Detection Kit (Product-License No. 24-759)
ㆍCtrl-X® EGFR T790M Mutation Detection Kit (Product-License No. 24-757)
ㆍCtrl-X® EGFR 19DEL Mutation Detection Kit (Product-License No. 24-756)
ㆍCtrl-X® ApoE Genotyping qPCR Kit (MFDS, Product-License No. 24-570)
ㆍCtrl-X® BRAF V600E Mutation Detection Kit (Product-License No. 24-758)
ㆍCtrl-X® KRAS G12C Mutation Detection Kit (Product-License No. 24-710)
ㆍCtrl-X® EGFR L858R Mutation Detection Kit (Product-License No. 24-759)
ㆍCtrl-X® EGFR T790M Mutation Detection Kit (Product-License No. 24-757)
ㆍCtrl-X® EGFR 19DEL Mutation Detection Kit (Product-License No. 24-756)
LOCATION
- Korea Office
-
F105~F107 Hifield, 66 Beolmal-ro, Dongan-gu,
Anyang-si, Gyeonggi-do, 14058, Korea -
+82-31-389-9990
-
contact@nuribio.com
- USA Office
-
8945 Research Drive, Irvine, CA 92618
-
contact@nuribio.com